Die Zukunft der Uroonkologie: Was muss geschehen, um den Bereich für die Urologie zu sichern?

P. Albers; J. Gschwend; O. Hakenberg

doi:10.1007/s00120-011-2539-1

Die Zukunft der Uroonkologie: Was muss geschehen, um den Bereich für die Urologie zu sichern?

Translated title of the contribution: The future of uro-oncology: What needs to be done to secure its place in the field of urology?

P. Albers
, J. Gschwend
, O. Hakenberg

Chair of Urology

Medical Faculty and University Hospital Düsseldorf
Urologische Klinik

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The specialty of urology has changed considerably with regard to the subspecialty of uro-oncology and requires more than just knowledge of hormone therapy for metastatic prostate cancer and standard treatment of testicular tumors. Many oncology centers offer specialized and interdisciplinary treatment, but often the process of navigating through the jungle of diagnostic workup and treatment is inadequate. Thus, clinical centers for uro-oncology must include specialists in pharmacological therapy for cancer and drug development who will work closely with the department of urology.

Translated title of the contribution	The future of uro-oncology: What needs to be done to secure its place in the field of urology?
Original language	German
Pages (from-to)	914-916
Number of pages	3
Journal	Urologe - Ausgabe A
Volume	50
Issue number	8
DOIs	https://doi.org/10.1007/s00120-011-2539-1
State	Published - Aug 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1007/s00120-011-2539-1

Cite this

@article{705e7f6f92cf4cbb8b566db2b34ac2dd,

title = "Die Zukunft der Uroonkologie: Was muss geschehen, um den Bereich f{\"u}r die Urologie zu sichern?",

abstract = "The specialty of urology has changed considerably with regard to the subspecialty of uro-oncology and requires more than just knowledge of hormone therapy for metastatic prostate cancer and standard treatment of testicular tumors. Many oncology centers offer specialized and interdisciplinary treatment, but often the process of navigating through the jungle of diagnostic workup and treatment is inadequate. Thus, clinical centers for uro-oncology must include specialists in pharmacological therapy for cancer and drug development who will work closely with the department of urology.",

keywords = "Long-term survivor, Possibilities for continuing education, Side effects, Uro-oncology, Urological cancer",

author = "P. Albers and J. Gschwend and O. Hakenberg",

year = "2011",

month = aug,

doi = "10.1007/s00120-011-2539-1",

language = "Deutsch",

volume = "50",

pages = "914--916",

journal = "Urologe - Ausgabe A",

issn = "0340-2592",

publisher = "Springer Medizin",

number = "8",

}

TY - JOUR

T1 - Die Zukunft der Uroonkologie

T2 - Was muss geschehen, um den Bereich für die Urologie zu sichern?

AU - Albers, P.

AU - Gschwend, J.

AU - Hakenberg, O.

PY - 2011/8

Y1 - 2011/8

N2 - The specialty of urology has changed considerably with regard to the subspecialty of uro-oncology and requires more than just knowledge of hormone therapy for metastatic prostate cancer and standard treatment of testicular tumors. Many oncology centers offer specialized and interdisciplinary treatment, but often the process of navigating through the jungle of diagnostic workup and treatment is inadequate. Thus, clinical centers for uro-oncology must include specialists in pharmacological therapy for cancer and drug development who will work closely with the department of urology.

AB - The specialty of urology has changed considerably with regard to the subspecialty of uro-oncology and requires more than just knowledge of hormone therapy for metastatic prostate cancer and standard treatment of testicular tumors. Many oncology centers offer specialized and interdisciplinary treatment, but often the process of navigating through the jungle of diagnostic workup and treatment is inadequate. Thus, clinical centers for uro-oncology must include specialists in pharmacological therapy for cancer and drug development who will work closely with the department of urology.

KW - Long-term survivor

KW - Possibilities for continuing education

KW - Side effects

KW - Uro-oncology

KW - Urological cancer

UR - https://www.scopus.com/pages/publications/80051791870

U2 - 10.1007/s00120-011-2539-1

DO - 10.1007/s00120-011-2539-1

M3 - Artikel

C2 - 21735269

AN - SCOPUS:80051791870

SN - 0340-2592

VL - 50

SP - 914

EP - 916

JO - Urologe - Ausgabe A

JF - Urologe - Ausgabe A

IS - 8

ER -

Die Zukunft der Uroonkologie: Was muss geschehen, um den Bereich für die Urologie zu sichern?

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this